Baseline Characteristics of Patients With and Without Bone Lesions Visible on CT Before Treatment with 177Lu-Octreotate
| Characteristic | Bone lesions visible on CT | Bone lesions not visible on CT | P |
| No. of patients | 31 | 11 | |
| No. of male patients | 19 | 7 | 1.00 |
| Age (y) | 0.85 | ||
| Mean | 61 | 62 | |
| Range | 43–77 | 51–79 | |
| Time from diagnosis to treatment (mo) | 0.91 | ||
| Median | 16 | 43 | |
| Range | 4–354 | 3–313 | |
| Time from development of bone metastases to treatment (mo) | 0.51 | ||
| Median | 4 | 3 | |
| Range | 1–44 | 1–14 | |
| Location of primary tumor (n) | |||
| Lung | 11 | 0 | 0.01* |
| Small intestine | 5 | 7 | |
| Colon/rectum | 2 | 0 | |
| Other | 4 | 0 | |
| Unknown | 9 | 4 | |
| Previous therapy (n) | 25 | 8 | 0.68 |
| Octreotide | 20 | 8 | 0.72 |
| Surgery | 16 | 7 | 0.73 |
| Radiotherapy | 4 | 2 | 0.64 |
| Chemotherapy | 3 | 1 | 1.00 |
| Embolization/chemoembolization | 3 | 1 | 1.00 |
| Liver radiofrequency ablation | 1 | 0 | 1.00 |
| Total administered dose (GBq) | 0.50 | ||
| Median | 29.7 | 29.9 | |
| Range | 22.0–30.2 | 14.7–30.3 | |
| 5-HIAA elevated (n) | 18 | 9 | 0.28 |
↵* Significant difference (Fisher exact test using Monte Carlo method).
Elevated 5-HIAA is ≥50 μmol/L in 24-h urine collection.